Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H14N2.ClH |
Molecular Weight | 234.725 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1=C2CCCCC2=NC3=C1C=CC=C3
InChI
InChIKey=ZUFVXZVXEJHHBN-UHFFFAOYSA-N
InChI=1S/C13H14N2.ClH/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;/h1,3,5,7H,2,4,6,8H2,(H2,14,15);1H
DescriptionSources: http://www.drugbank.ca/drugs/DB00382Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/cognex.html
Sources: http://www.drugbank.ca/drugs/DB00382
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/cognex.html
Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.
CNS Activity
Originator
Sources: http://www.alzforum.org/therapeutics/tacrine
Curator's Comment: Originally developed by Warner-Lambert Co.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 Sources: http://www.drugbank.ca/drugs/DB00382 |
500.0 nM [IC50] | ||
Target ID: CHEMBL1914 Sources: http://www.drugbank.ca/drugs/DB00382 |
23.0 nM [IC50] | ||
Target ID: CHEMBL2190 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15834447 |
0.46 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Cognex Approved UseCognex® (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Launch Date1993 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TACRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
91.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TACRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TACRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (21 patient) Sources: Vomiting (21 patient) Anorexia (21 patient) Dyspepsia (21 patient) Diarrhea (21 patient) Abdominal pain (21 patient) |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: Page: p. 5 |
Disc. AE: Transaminases increased, Atrial fibrillation... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Page: p. 5Atrial fibrillation (1 patient) Dyspnea (1 patient) Chest pain (1 patient) |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
Disc. AE: Transaminases increased, Nausea... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Page: p. 5Nausea (1 patient) Vomiting (1 patient) Pallor (1 patient) Vasodilatation (1 patient) Sweating increased (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 21 patient Disc. AE |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Anorexia | 21 patient Disc. AE |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Diarrhea | 21 patient Disc. AE |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Dyspepsia | 21 patient Disc. AE |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Nausea | 21 patient Disc. AE |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Vomiting | 21 patient Disc. AE |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: |
Atrial fibrillation | 1 patient Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: Page: p. 5 |
Chest pain | 1 patient Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: Page: p. 5 |
Dyspnea | 1 patient Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: Page: p. 5 |
Transaminases increased | 1 patient Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: Page: p. 5 |
Nausea | 1 patient Disc. AE |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
Pallor | 1 patient Disc. AE |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
Sweating increased | 1 patient Disc. AE |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
Transaminases increased | 1 patient Disc. AE |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
Vasodilatation | 1 patient Disc. AE |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
Vomiting | 1 patient Disc. AE |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p. 5 |
unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: Page: p. 5 |
PubMed
Title | Date | PubMed |
---|---|---|
An appraisal of tacrine-extended suxamethonium. | 1970 Feb |
|
Ketamine-induced postanesthetic delirium attenuated by tetrahydroaminoacridine. | 1974 Jul |
|
Suxamethonium apnoea masked by tetrahydroaminacrine. | 1978 Jul-Aug |
|
Amino acridines action on Friend's retrovirus in relation to their molecular ionization. | 1989 |
|
Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. | 1989 Nov 28 |
|
A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. | 1990 Nov |
|
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. | 1992 |
|
Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. | 1993 Mar |
|
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. | 1993 Nov 30 |
|
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. | 1995 Aug |
|
Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain. | 1995 Dec 27 |
|
Delirium caused by tacrine and ibuprofen interaction. | 1996 Jun |
|
Convulsive effects of tacrine. | 1996 May 11 |
|
Adverse interaction of tacrine and haloperidol. | 1996 Nov |
|
Therapeutic approaches to age-associated neurocognitive disorders. | 2001 Sep |
|
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs. | 2002 Dec |
|
The evaluation of cognitive function in the dementias: methodological and regulatory considerations. | 2003 Mar |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats. | 2006 |
|
2006 Jun |
||
Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7. | 2006 May |
|
Progress update: Pharmacological treatment of Alzheimer's disease. | 2007 |
|
WITHDRAWN: Tacrine for Alzheimer's disease. | 2007 Jul 18 |
|
Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease. | 2007 Jul 25 |
|
Allosteric modulation of muscarinic acetylcholine receptors. | 2007 Sep |
|
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. | 2008 Dec |
|
Cholinesterase inhibitors for delirium. | 2008 Jan 23 |
|
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. | 2008 Jun 12 |
|
1-Phenyl-6,7,8,9-hexa-hydro-1H,5H-cyclo-hepta-[1',2':2,3]pyrido[6,5-c]pyrazol-4-amine: a new tacrine analogue. | 2008 May 10 |
|
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. | 2008 Oct |
|
The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats. | 2008 Oct |
|
Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. | 2008 Oct 15 |
|
Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. | 2008 Sep 25 |
|
Cholinergic influence on memory stages: A study on scopolamine amnesic mice. | 2009 Aug |
|
Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. | 2009 Feb 6 |
|
Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. | 2009 Jan |
|
Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration. | 2009 Nov |
|
Coupling an HCN2-expressing cell to a myocyte creates a two-cell pacing unit. | 2009 Nov 1 |
|
Contribution of the d-Serine-Dependent Pathway to the Cellular Mechanisms Underlying Cognitive Aging. | 2010 |
|
Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine. | 2010 |
|
A second-generation device for automated training and quantitative behavior analyses of molecularly-tractable model organisms. | 2010 Dec 17 |
|
Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones. | 2010 Feb |
|
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. | 2010 Jan 12 |
|
Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity. | 2010 Jul 5 |
|
Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. | 2011 Aug |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. | 2013 Dec |
|
Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. | 2013 Mar 25 |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
|
N-palmitoyl serotonin alleviates scopolamine-induced memory impairment via regulation of cholinergic and antioxidant systems, and expression of BDNF and p-CREB in mice. | 2015 Dec 5 |
Sample Use Guides
Oral
Initially, 10 mg 4 times daily for at least 4 weeks.
If well tolerated and increased serum ALT concentrations have not occurred, increase dosage to 20 mg 4 times daily; if tolerated, increase dosage in 40-mg daily increments (divided into 4 doses daily) at 4-week intervals up to a maximum of 160 mg daily (40 mg 4 times daily).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15834447
Tacrine (0.01-10 uM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 uM vs. 0.29 uM, respectively).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1684-40-8
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
2723754
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL95
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
72108
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
4966RNG0BU
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
216-867-5
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
235972
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB04665MIG
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
DTXSID1026112
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
AA-35
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
m10424
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000084787
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
C47742
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY | |||
|
DBSALT001053
Created by
admin on Fri Dec 15 15:10:50 GMT 2023 , Edited by admin on Fri Dec 15 15:10:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD